Open Access

Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome (Review)

  • Authors:
    • Yuna Chai
    • Yusheng Huang
    • Hongmei Tang
    • Xing Tu
    • Jianbo He
    • Ting Wang
    • Qingye Zhang
    • Fen Xiong
    • Detang Li
    • Zhenwen Qiu
  • View Affiliations

  • Published online on: February 20, 2017     https://doi.org/10.3892/etm.2017.4133
  • Pages: 1187-1193
  • Copyright: © Chai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Irritable bowel syndrome (IBS) is a functional bowel disease with a complicated etiopathogenesis, often characterized by gastrointestinal motility disorder and high visceral sensitivity. IBS is a comprehensive multi‑systemic disorder, with the interaction of multiple factors, such as mental stress, intestinal function and flora, heredity, resulting in the disease. The existence of a common mechanism underlying the aforementioned factors is currently unknown. The lack of therapies that comprehensively address the disease symptoms, including abdominal pain and diarrhea, is a limitation of current IBS management. The current review has explored the role of the SCF/c‑Kit receptor/ligand system in IBS. The SCF/c-Kit system constitutes a classical ligand/receptor tyrosine kinase signaling system that mediates inflammation and smooth muscle contraction. Additionally, it provides trophic support to neural crest‑derived cell types, including the enteric nervous system and mast cells. The regulation of SCF/c‑Kit on the interstitial cells of Cajal (ICC) suggest that it may play a key role in the aberrant intestinal dynamics and high visceral sensitivity observed in IBS. The role of the SCF/c‑Kit system in intestinal motility, inflammation and nerve growth has been reported. From the available biomedical evidence on the pathogenesis of IBS, it has been concluded that the SCF-c-Kit system is a potential therapeutic target for rational drug design in the treatment of IBS.
View Figures
View References

Related Articles

Journal Cover

April-2017
Volume 13 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chai Y, Huang Y, Tang H, Tu X, He J, Wang T, Zhang Q, Xiong F, Li D, Qiu Z, Qiu Z, et al: Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome (Review). Exp Ther Med 13: 1187-1193, 2017
APA
Chai, Y., Huang, Y., Tang, H., Tu, X., He, J., Wang, T. ... Qiu, Z. (2017). Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome (Review). Experimental and Therapeutic Medicine, 13, 1187-1193. https://doi.org/10.3892/etm.2017.4133
MLA
Chai, Y., Huang, Y., Tang, H., Tu, X., He, J., Wang, T., Zhang, Q., Xiong, F., Li, D., Qiu, Z."Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome (Review)". Experimental and Therapeutic Medicine 13.4 (2017): 1187-1193.
Chicago
Chai, Y., Huang, Y., Tang, H., Tu, X., He, J., Wang, T., Zhang, Q., Xiong, F., Li, D., Qiu, Z."Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome (Review)". Experimental and Therapeutic Medicine 13, no. 4 (2017): 1187-1193. https://doi.org/10.3892/etm.2017.4133